Caricamento...
Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines
Background: Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the Australian Government Therapeutic Goods Administration (TGA) amended the indication to restrict use in BPSD to patients with...
Salvato in:
| Pubblicato in: | Pharmacy (Basel) |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6789876/ https://ncbi.nlm.nih.gov/pubmed/31336574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmacy7030100 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|